CMN 571 Unit 1 Test – 2026/2027 Edition
– 50 Questions with 100% Verified
Correct Answers
Questions with Step-by-Step Answers | 100% Verified | A+ Graded Review
OVERVIEW:
CMN 571 Unit 1 Test – 2026/2027 Edition covers pediatric immunizations, COVID
shared decision-making, influenza, seasonal RSV, Nirsevimab dosing, VIS
documentation, vaccine contraindications, active, passive, herd immunity,
newborn screening, growth tracking, developmental milestones, motor, language,
toilet training, reflexes, breastfeeding, supplementation, dental home, anticipatory
guidance, food allergy introduction, primary, secondary, tertiary prevention,
ACEs, social determinants, and autism MCHAT screening protocols
comprehensively.
Answers are in bold Green, with rationales after.
1. According to CDC guidance in the notes, COVID-19 vaccine decision-making for
ages 6 months to 17 years is based on:
A. Mandatory requirement
B. Shared decision making
C. Contraindicated
D. Only if immunocompromised
Rationale: Notes state COVID vaccine is based on shared decision making for 6
months to 17 years.
2. Influenza vaccine is recommended starting at what age?
A. Birth
, B. 2 months
C. 6 months and older
D. 12 months and older
Rationale: Notes list Influenza vaccine: 6 months and older.
3. RSV protection via Maternal or Infant strategy is seasonal during:
A. January to June
B. April to September
C. October through March
D. Year-round
Rationale: Notes specify Maternal or Infant RSV -> October through March.
4. A newborn born in December can receive RSV antibody within:
A. First week of life
B. First month of life
C. At 2 months
D. At 6 months
Rationale: Baby can receive within first week of life if born through those months (Oct-
Mar).
5. Nirsevimab dosing for an infant age <8 months weighing 6 kg is:
A. 25mg
B. 50mg
C. 100mg
D. 200mg as 2x100mg
Rationale: For <8 months: 50mg if <5kg; 100mg if >5kg. 6kg >5kg so 100mg.
– 50 Questions with 100% Verified
Correct Answers
Questions with Step-by-Step Answers | 100% Verified | A+ Graded Review
OVERVIEW:
CMN 571 Unit 1 Test – 2026/2027 Edition covers pediatric immunizations, COVID
shared decision-making, influenza, seasonal RSV, Nirsevimab dosing, VIS
documentation, vaccine contraindications, active, passive, herd immunity,
newborn screening, growth tracking, developmental milestones, motor, language,
toilet training, reflexes, breastfeeding, supplementation, dental home, anticipatory
guidance, food allergy introduction, primary, secondary, tertiary prevention,
ACEs, social determinants, and autism MCHAT screening protocols
comprehensively.
Answers are in bold Green, with rationales after.
1. According to CDC guidance in the notes, COVID-19 vaccine decision-making for
ages 6 months to 17 years is based on:
A. Mandatory requirement
B. Shared decision making
C. Contraindicated
D. Only if immunocompromised
Rationale: Notes state COVID vaccine is based on shared decision making for 6
months to 17 years.
2. Influenza vaccine is recommended starting at what age?
A. Birth
, B. 2 months
C. 6 months and older
D. 12 months and older
Rationale: Notes list Influenza vaccine: 6 months and older.
3. RSV protection via Maternal or Infant strategy is seasonal during:
A. January to June
B. April to September
C. October through March
D. Year-round
Rationale: Notes specify Maternal or Infant RSV -> October through March.
4. A newborn born in December can receive RSV antibody within:
A. First week of life
B. First month of life
C. At 2 months
D. At 6 months
Rationale: Baby can receive within first week of life if born through those months (Oct-
Mar).
5. Nirsevimab dosing for an infant age <8 months weighing 6 kg is:
A. 25mg
B. 50mg
C. 100mg
D. 200mg as 2x100mg
Rationale: For <8 months: 50mg if <5kg; 100mg if >5kg. 6kg >5kg so 100mg.
